Do you think cannabis will be fully rescheduled before the end of 2026?
Max Vansluys | President | Dialed In Gummies
Honestly, I don’t think it will be fully rescheduled before the end of 2026. There’s still a significant amount of regulatory process and red tape that needs to be worked through before it gets across the finish line. Obviously, everyone in the industry would like to see it happen sooner rather than later because it would create meaningful opportunities for operators and retailers.
That said, one of the things I’m most excited about is the potential for expanded medical research. At Dialed In, we’ve always believed cannabis has a strong wellness and therapeutic component, and we’re already seeing more white papers and research emerge. As the science and research continue to grow, it opens the door for brands like ours to have more informed conversations around the medical and functional side of cannabis.
Shavon Sullivan Wright | CEO | The Grass Cab
I hope that I’m wrong, but I don’t think cannabis will be fully rescheduled by the end of 2026. The industry isn’t moving as one force. Well-funded, medical multi-state operators have been able to push policy in their favor, while hemp and adult-use markets remain fragmented and divided. Until the industry comes together with a unified voice, real policy change will keep stalling.
Chris Fontes | CEO | High Spirits
No, I think it is unlikely that we will see a complete reschedule by the end of 2026. Getting medical to Schedule III is proving to be difficult, and while that is already technically done, lawsuits and other administrative issues will sadly prevent this from triggering a complete reschedule.
For now, we will have to be satisfied with hemp and medical cannabis no longer being Schedule I. That said, hemp can serve most of the recreational market already, depending on what the federal government does in the next six months.
Fadi Boumitri | CEO | Ascension Biomedical
The federal government hearings on moving cannabis to Schedule III start in June. The administration ordered those hearings to conclude by July 15. Any resulting rule takes effect 90 days later (landing just before the November elections). This timing is likely not a coincidence.
Sasha Nutgent | VP of Cannabis Retail | Housing Works Cannabis Co
I’m somewhat of a realist, so I’m banking on cannabis not being fully rescheduled by the end of this year. While there’s been a lot of discussion about what rescheduling may look like on the adult use recreational side, there’s still a lot to consider, especially all the legal processes and hearings that will need to happen before we completely move forward with a full reschedule.
Inesa Ponomariovaite | CEO | Nesa’s Hemp
We’re closer than we’ve ever been, but “fully rescheduled” is not what I believe will happen. The shift from Schedule I to Schedule III under the U.S. Drug Enforcement Administration has momentum, but the reality is that regulatory change tends to move more slowly than public sentiment and industry readiness. What matters more than timing is how it’s done. If rescheduling happens without clear federal frameworks around testing, labeling and interstate commerce, it could create just as much confusion as progress, especially for hemp-derived products that already sit in a gray area post-2018 Farm Bill.
Ryan Hunter | Chief Revenue Officer | Spherex
I think it would be logical to assume that cannabis will be moved to Schedule III by the end of 2026. The federal government now has at least three different categorizations for cannabis. The exact same products have multiple regulatory paradigms. Logically, this is not how the CSA is supposed to work. That being said, this administration has been far from logical, so who really knows!?!
Brett Harris | CEO | LuvBuds
I hope so, but hope is not a strategy. The industry deserves a more rational framework, and rescheduling would be a major step. The important thing is that there finally appears to be real movement. Progress is appreciated, and we are further along than we were just a few weeks ago. That said, until all of the versions, details and possible outcomes are fully vetted, we are not making business decisions that set us up for disappointment.
Ali Garawi | CEO | Muha Meds
The move toward Schedule III already signals a meaningful shift at the federal level. That said, it still has to navigate through formal rulemaking and could face legal delays. From an operator standpoint, it’s less about a specific deadline and more about staying several steps ahead in how you structure and position the business for what comes next.
Michael Mejer | Founder | Green Lane Communication
I believe the momentum is real, but I’d be cautious about assuming full rescheduling happens before the end of 2026. The industry often mistakes political discussion for operational change. What feels more likely is continued movement toward a federally tolerated, highly regulated framework that rewards companies already operating with discipline and a rigorous compliance infrastructure.
Kevin Hart | CEO | Green Check
Close, but not fully in my opinion. While all the recent progress has centered around medical, and let’s not forget the all-but-certain November closure of the hemp loophole, this administration has been very clear, on every occasion, that they have no intention of “legalizing” cannabis. It would just be too much for the federal and states together to unwind in this time window.
Alleh Lindquist | CEO | FloraWorks
Parts of medical cannabis have already been moved to Schedule III, and a hearing is set to consider broader rescheduling. At the same time, a new program through the Centers for Medicare and Medicaid Services is introducing cannabinoid options into care under clinician oversight. For that program to remain viable into its planned 2027 expansion, both rescheduling and updates to the hemp framework will likely be required. That’s what’s driving momentum.
Brian Staffa | Managing partner | High Revival Holdings
As jaded as many industry veterans are, myself included, I truly think it’s going to happen in the last week of October 2026, right before the mid-terms after the procedural requirements are met. It’s a long time coming and while not the end of the battle, it’s an enormous incremental step in the right direction.
Alex Gonzalez | President | Calyx Containers
I don’t see a realistic path to full rescheduling before the end of 2026. The federal movement so far has been narrow, medical and research-oriented, not a real embrace of commercial cannabis at all. Adult-use is even further away. Until Washington is willing to reconcile federal law with state-regulated markets, operators should plan around uncertainty, not relief.
Ashley Infausto | CEO | Scoutwell
Short answer: No, and it’s a bit of a distraction.
Rescheduling won’t fix what’s actually broken: inconsistent standards, weak product efficacy and a lack of consumer trust. From where I sit, the industry is already ahead of policy. The brands that win won’t wait for federal validation, they’ll be the ones delivering real, evidence-backed outcomes now.
Danielle Wildstein | Founder | Blue Oak Dispensary
I expect progress, but not full rescheduling by the end of 2026. This is a gradual, medical-first shift — not a sweeping federal change — and policymaking moves slowly. Key questions and complexities still need to be resolved before adult-use cannabis can be rescheduled. Until federal policy aligns more closely with state markets, the industry will remain in a transitional phase.
Colin Fraser | CEO | Upling
I think it’s moving in that direction, but I wouldn’t bet everything on the timeline. Policy doesn’t move as fast as the market. We’ve already seen momentum toward rescheduling, and that’s a big signal — but “fully resolved” by 2026 depends on politics, not just logic.
What I do know is this: the demand is already here. Consumers, patients and businesses are operating like it’s normalized. So at Upling, we don’t wait on policy — we build for where the world is going. When federal reform hits, the companies that win will be the ones already scaled, compliant and trusted.
Jason Vedadi | CEO | Story Cannabis
The shift to Schedule III was a major catalyst, and I hope to see full rescheduling by year-end 2026. It is the logical next step to invigorate the market with new investors and product innovations. Removing the burden of excessive taxation will further allow the industry to professionalize and scale at a national level. The ceiling for this industry is finally starting to lift.
Chris Mapson | Executive Vice President of Marketing | Cannatrol
Although we are hopeful full rescheduling can occur by the end of the year, it seems unlikely. We have heard discussions and predictions around rescheduling for many years, dating back to the earliest state-regulated recreational markets. So there is a degree of caution and skepticism whenever rescheduling is discussed. While the recent progress is extremely encouraging and represents one of the most significant developments the industry has seen, there are still multiple regulatory, political and administrative steps that would need to occur before the process is fully finalized.
That said, the momentum toward greater federal recognition and oversight is clearly moving in a positive direction. Even the current conversations around rescheduling are already influencing how operators think about compliance, consistency, GMP readiness and long-term business planning.
Jeremy Zachary | CEO | Zen Brands Intl.
No, I don’t believe cannabis will be fully rescheduled by this year’s end. The Feds have slowly begun the process of shifting the pendulum into a regulated environment for the industry by rescheduling of medical cannabis to Schedule III. Keep in mind, since the Executive Office made the call, the DOJ, DEA, FDA and IRS all need to align with their own regulation around the treatment of cannabis businesses. While the DEA’s registration portal has opened, they are still working through details. I think we’ll all be happy to realize the full implications and guidelines of med rescheduling by year’s end.
Sandra Bergman | Founder & CEO | ESBE Marketing
I highly doubt it. We’ve seen this process start previously and then stall more than once. Plus, since the current executive order covers only medical, it benefits only a portion of the companies and markets, leaving those serving recreational/adult-use out in the cold. Since the majority of dollars and demand are in the rec/AU sector, I could see those stakeholders pushing back on the current rescheduling efforts.
Eric Sellew | CEO | ZZZ’s Collective
If by “full” you mean adult use and medical? I don’t. I think they intentionally separated them out and there is going to be a protracted battle over adult use rescheduling.

